Presence of HIV-1 neutralizing IgA antibodies in primary HIV-1 infected patients

Scandinavian Journal of Infectious Diseases

Volumn 36, Issue 9, 2004, Pages 663-669

  Söderlund, Johan ^a   Hirbod, Taha ^a   Goh, Li Ean ^b   Andersson, Jan ^c   Broliden, Kristina ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b GLAXOSMITHKLINE   (United Kingdom)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; CARBOVIR; CD8 ANTIGEN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; NEUTRALIZING ANTIBODY;

ANTIBODY DETECTION; ANTIBODY RESPONSE; ARTICLE; CELLULAR IMMUNITY; CLADISTICS; CLINICAL ARTICLE; CONTROLLED STUDY; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGLOBULIN BLOOD LEVEL; MALE; NONHUMAN; PHENOTYPIC VARIATION; SEMEN ANALYSIS; T LYMPHOCYTE; VIREMIA; VIRUS ISOLATION; VIRUS REPLICATION;

ANTIBODIES, ANTI-IDIOTYPIC; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COHORT STUDIES; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOGLOBULIN A; MALE; PROGNOSIS; RISK FACTORS; TREATMENT OUTCOME;

EID: 4644289578     PISSN: 00365548     EISSN: None     Source Type: Journal    
DOI: 10.1080/00365540410020857     Document Type: Article

References (24)

1. Lindbäck S, Karlsson AC, Mittler J, Blaxhult A, Carlsson M, Briheim G, et al. Viral dynamics in primary HIV-1 infection. Karolinska Institute Primary HIV Infection Study Group. AIDS 2000; 14: 2283-91.
2. Altfeld M, Rosenberg ES, Shankarappa R, Mukherjee JS, Hecht FM, Eldridge RL, et al. Cellular immune responses and viral diversity in individuals treated during acute and early HIV-1 infection. J Exp Med 2001; 193: 169-80.
3. Rosenberg ES, Altfeld M, Poon SH, Phillips MN, Wilkes BM, Eldridge RL, et al. Immune control of HIV-1 after early treatment of acute infection. Nature 2000; 407: 523-6.
4. Richman DD, Wrin T, Little SJ, Petropoulos CJ. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci USA 2003; 100: 4144-9.
5. Kaul R, Plummer F, Clerici M, Bomsel M, Lopalco L, Broliden K. Mucosal IgA in exposed, uninfected subjects: evidence for a role in protection against HIV infection. AIDS 2001; 15: 431-2.
6. Devito C, Broliden K, Kaul R, Svensson L, Johansen K, Kiama P, et al. Mucosal and plasma IgA from HIV-1-exposed uninfected individuals inhibit HIV-1 transcytosis across human epithelial cells. J Immunol 2000; 165: 5170-6.
7. Devito C, Hinkula J, Kaul R, Lopalco L, Bwayo JJ, Plummer F, et al. Mucosal and plasma IgA from HIV-exposed seronegative individuals neutralize a primary HIV-1 isolate. AIDS 2000; 14: 1917-20.
8. Lo Caputo S, Trabattoni D, Vichi F, Piconi S, Lopalco L, Villa ML, et al. Mucosal and systemic HIV-1-specific immunity in HIV-1-exposed but uninfected heterosexual men. AIDS 2003; 17: 531-9.
9. Baba TW, Liska V, Hofmann-Lehmann R, Vlasak J, Xu WD, Ayehunie S, et al. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat Med 2000; 6: 200-6.
10. Mascola JR, Stiegler G, VanCott TC, Katinger H, Carpenter CB, Hanson CE, et al. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med 2000; 6: 207-10.
11. Montefiori DC, Hill TS, Vo HT, Walker BD, Rosenberg ES. Neutralizing antibodies associated with viraemia control in a subset of individuals after treatment of acute human immunodeficiency virus type 1 infection. J Virol 2001; 75: 10200-7.
12. Goh LE, Perrin L, Hoen B, Cooper D, Phillips A, Janossy G, et al. Study protocol for the evaluation of the potential for durable viral suppression after quadruple HAART with or without HIV vaccination: the QUEST study. HIV Clin Trials 2001; 2: 438-44.
13. Karlsson A, Parsmyr K, Sandstrom E, Fenyo EM, Albert J. MT-2 cell tropism as prognostic marker for disease progression in human immunodeficiency virus type 1 infection. J Clin Microbiol 1994; 32: 364-70.
14. Shi Y, Albert J, Francis G, Holmes H, Fenyo EM. A new cell line-based neutralization assay for primary HIV type 1 isolates. AIDS Res Hum Retroviruses 2002; 18: 957-67.
15. Mazzoli S, Trabattoni D, Lo Caputo S, Piconi S, Ble C, Meacci F, et al. HIV-specific mucosal and cellular immunity in HIV-seronegative partners of HIV-seropositive individuals. Nat Med 1997; 3: 1250-7.
16. de Carvalho Nicacio C, Bjorling E, Lundkvist A. Immunoglobulin A responses to Puumala hantavirus. J Gen Virol 2000; 81: 1453-61.
17. Fagarasan S, Kinoshita K, Muramatsu M, Ikuta K, Honjo T. In situ class switching and differentiation to IgA-producing cells in the gut lamina propria. Nature 2001; 413: 639-43.
18. Lenz P, Day PM, Pang YY, Frye SA, Jensen PN, Lowy DR, Schiller JT. Papillomavirus-like particles induce acute activation of dendritic cells. J Immunol 2001; 166: 5346-55.
19. Ruedl C, Storni T, Lechner F, Bachi T, Bachmann MF. Cross-presentation of virus-like particles by skin-derived CD8(-) dendritic cells: a dispensable role for TAP. Eur J Immunol 2002; 32: 818-25.
20. Zhu T, Corey L, Hwangbo Y, Lee JM, Learn GH, Mullins JI, et al. Persistence of extraordinarily low levels of genetically homogeneous human immunodeficiency virus type 1 in exposed seronegative individuals. J Virol 2003; 77: 6108-16.
21. Morris L, Binley JM, Clas BA, Bonhoeffer S, Astill TP, Kost R, et al. HIV-1 antigen-specific and -non-specific B-cell responses are sensitive to combination antiretroviral therapy. J Exp Med 1998; 188: 233-45.
22. Binley JM, Trkola A, Ketas T, Schiller D, Clas B, Little S, et al. The effect of highly active antiretroviral therapy on binding and neutralizing antibody responses to human immunodeficiency virus type 1 infection. J Infect Dis 2000; 182: 945-9.
23. Wei X, Decker JM, Wang S, Hui H, Kappes JC, Wu X, et al. Antibody neutralization and escape by HIV-1. Nature 2003; 422: 307-12.
24. Kim JH, Mascola JR, Ratto-Kim S, VanCott TC, Loomis-Price L, Cox JH, et al. Selective increases in HIV-specific neutralizing antibody and partial reconstitution of cellular immune responses during prolonged, successful drug therapy of HIV infection. AIDS Res Hum Retroviruses 2001; 17: 1021-34.